NSL1 activators belong to a category of chemical agents that are specifically designed to modulate the activity of the protein NSL1, which is a part of the Non-Specific Lethal complex (NSL), a multiprotein assembly that plays a crucial role in the regulation of gene expression in eukaryotic cells. The NSL complex is known to be involved in various cellular processes by modulating the transcription of a broad set of genes, including those involved in cell growth and metabolism. NSL1 activators interact with the NSL1 protein, enhancing its function within the NSL complex. This enhancement influences the complex's ability to carry out its role in the fine-tuning of chromatin structure and function, which in turn impacts the transcriptional landscape of the cell. The precise mechanisms through which NSL1 activators exert their effects involve direct binding to NSL1, leading to conformational changes or stabilization of the protein in a state that promotes its interaction with other components of the NSL complex or with chromatin itself.
The chemical properties of NSL1 activators are diverse, reflecting the complexity of modulating a protein-protein interaction within a cell. These activators are often small molecules, which possess the ability to penetrate cellular membranes and reach intracellular targets without significant degradation. The structural motifs within NSL1 activators are specifically crafted to interact with NSL1's unique binding sites, and this interaction is fine-tuned through an iterative process of chemical synthesis and biological testing. By precisely targeting NSL1, activators can modulate the complex's activity without broad effects on other unrelated biological pathways, ensuring a high degree of specificity in their mode of action.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can increase protein levels by preventing degradation, potentially increasing NSL1 stability and concentration. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
CDK inhibitor that could lead to cell cycle arrest, enhancing the assembly of kinetochore complexes and possibly NSL1 activation. | ||||||
BI6727 | 755038-65-4 | sc-364432 sc-364432A sc-364432B sc-364432C sc-364432D | 5 mg 50 mg 100 mg 500 mg 1 g | $150.00 $1050.00 $1665.00 $3329.00 $4382.00 | 1 | |
PLK1 inhibitor that may disrupt normal spindle formation, increasing the need for kinetochore stabilization and potentially upregulating NSL1. | ||||||
S-Trityl-L-cysteine | 2799-07-7 | sc-202799 sc-202799A | 1 g 5 g | $32.00 $66.00 | 6 | |
Inhibitor of the mitotic kinesin Eg5, which could lead to spindle defects and compensatory upregulation of kinetochore components including NSL1. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that could disrupt chromosome alignment and the checkpoint response, potentially leading to increased NSL1 at kinetochores. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
CDK inhibitor that can arrest cells in G2/M phase, possibly leading to increased kinetochore assembly and NSL1 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can affect spindle dynamics and checkpoint activation, possibly increasing NSL1 function at kinetochores. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Aurora kinase inhibitor that can lead to abnormal mitotic spindle assembly, potentially requiring enhanced NSL1 function for correction. | ||||||